Efficacy of imatinib dose escalation in Chinese gastrointestinal stromal tumor patients

Figure 1 Progression-free survival for all patients. Forty-eight patients (92.3%) had disease progression after imatinib 600 mg/d treatment, and the median PFS of all the 52 patients was 17 wk (95% CI: 3.9-30.1). PFS: Progression-free survival; CI: Confidence interval.

Figure 2 The median progression-free survival for partial response or stable disease patients was 51 wk (95% CI: 26. 8-75.2) and that of patients with progressive disease was 12 wk (95% CI: 10.6-13.4) (P < 0.001). PR: Partial response; SD: Stable disease; CI: Confidence interval.

Figure 3 Median overall survival of all patients starting from the first prescription of 600 mg/d imatinib. Median OS was 81 wk (95% CI: 36.2-125.8). OS: Overall survival; CI: Confidence interval.

Figure 4 Progression-free survival of patients by gene mutation. PFS of the patients with exon 9 mutation, exon 11 mutation, and wild type were 47 wk, 21 wk, and 8 wk, respectively, but the difference was not significant (P = 0.083). PFS: Progression-free survival.